July to August 2025
Osivax announced $19.5 million in funding from the US Biomedical Advanced Research and Development Authority (BARDA) to advance development of OVX835, including preparation for a large-scale efficacy trial and process development for manufacturing scale-up (press release 8-26-2025)
NIAID began recruitment for a new phase 1 trial to examine the safety, tolerability, and immunogenicity of a quadrivalent influenza HA stem nanoparticle vaccine, SteMos1, with and without ALFQ adjuvant (NCT07111078)
Preclinical study at Iowa State University of an intranasal polymer-based nanoparticle vaccine with H3 antigen from an equine H3N8 virus and nucleoprotein antigen from an H3N2 virus, aimed at eliciting broadly protective humoral and cellular immune responses, reported in Siddoway 2025
“Beads-on-a-string” (BOAS) multivalent immunogens, tandemly linked HA subtypes conjugated to ferritin nanoparticles, developed at Harvard University, reported in Lamson 2025 (preprint)
Dental floss-based mucosal vaccine containing conserved M2e antigens on a nanoparticle platform reported in Ingrole 2025
June to July 2025
Preclinical evaluation of sequential vaccination with a conserved HA stalk-focused vaccine (group 2 chimeric HA inactivated split vaccine) and an adjuvanted recombinant NA protein (rNA-N2-MPP), reported in Puente-Massaguer 2025
Results of a phase 1b randomized, double-blind, placebo-controlled trial of the safety, reactogenicity, and immunogenicity of FluGen’s intranasal M2SR H3N2 next-generation influenza vaccine in children, posted in NCT04960397
Preclinical evaluation of broadly protective immune responses elicited by computationally optimized broadly-reactive H1 and H3 antigens expressed from a self-amplifying mRNA vector platform (samRNA-COBRA), reported in Pierce 2025
Moderna reported safety and immunogenicity results from a phase 1/2 trial (NCT05333289) of mRNA-based next-generation influenza vaccine candidates (mRNA-1020 and mRNA-1030) encoding HA and NA antigens at different HA:NA ratios in Rudman Spergel 2025.
Relative vaccine efficacy against influenza illness elicited by Moderna’s mRNA-1010 next-generation candidate, compared with licensed seasonal influenza vaccine, in a randomized controlled phase 3 trial (NCT06602024) in 40,805 adults aged 50 and older in 11 countries, reported in a 6/30/25 press release; Moderna plans to publish the data in a peer-reviewed journal and submit an application for regulatory approval.
Preliminary safety, immunogenicity, and reactogenicity data from a phase 3 trial of Novavax’s combination COVID+influenza nanoparticle vaccine candidate (CIC) and next-generation influenza vaccine candidate (Nano-Flu, tNIV) in adults aged 65 and older, reported in a 6/11/25 press release
Preclinical evaluation of mucosal and systemic humoral and cellular immune responses induced by intranasal administration of an adjuvanted recombinant NA-based influenza vaccine candidate, rNA-N1-MPP, reported in Vasilev 2025
Preclinical evaluation of broadly protective immune responses induced by mucosal immunization with conserved NP antigens from influenza A and B viruses linked to the autophagy-inducing peptide C5 based on a bovine adenoviral vector, reported in Wang 2025
May to June 2025
Reactogenicity, safety, and immunogenicity of Osivax’s NP-based OVX836 vaccine candidate co-administered with a licensed seasonal influenza vaccine in a Phase 2a trial NCT05284799, published in Groth 2025
Preclinical evaluation of intranasal delivery of a multi-subtype consensus NA-M2e VLP vaccine candidate, reported in Raha 2025
Development of recombinant H3 COBRA HA antigens using A(H3N2) HA sequences circulating from 2018-2022 to elicit broadly protective antibodies against A(H3N2) strains in animal models, reported in Allen 2025
Results of a Phase 3 trial NCT06097273 of Moderna’s mRNA-1083 combination COVID+influenza vaccine candidate, published in Rudman Spergel 2025
Preclinical evaluation of a centralized consensus NA immunogen delivered via an adenovirus vector, reported in Pekarek 2025
Results of a Phase 1/2 trial NCT05052697 of Pfizer’s next-generation quadrivalent mRNA vaccine candidate, qIRV, reported in Branche 2025
April to May 2025
EU-funded public-private partnership formed to develop Vivaldi's DeltaFLU vaccine candidate, announced in Cnossen 2025
US HHS funding announced to develop NIAID's BPL-1357, as noted in STAT and KFF Health News. Results of NIAID's BPL-1357 Phase 1 trial NCT05027932 posted on Clinicaltrials.gov
Analysis of broadly protective immune responses in newborn NHPs to NIAID’s HA-stem ferritin nanoparticle vaccine (H1ssF+AddaVax) in Crofts 2025
Results of Moderna's mRNA-1010 Phase 3 trials NCT05415462 and NCT05566639 published in Kandinov 2025
Analysis of B cell responses against broadly protective epitopes of the HA stalk domain following chimeric HA vaccination, published in Guthmiller 2025
New Phase 1 trial NCT06863142 of NIAID’s FluMos-v2 mosaic hexavalent nanoparticle vaccine with and without ALFQ adjuvant